We next examined RNA sequencing data from the TARGET AML cohort including 8 CBFA2T3::GLIS2 fusion positive samples compared to 292 AML samples without the fusion (Fig. 3A, Supplemental Table S3). The gene discussed is CBFA2T3; the disease is acute myeloid leukemia.